New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Prophylaxis against venous thromboembolism (VTE) is considered standard of care. Appropriate chemoprophylaxis for VTE has been mandated by the United States government agencies and consumer groups. However, controversies exist regarding the most clinically relevant and safe chemoprophylaxis protocols in patients undergoing joint replacement surgery. Thus, this paper reviews the clinical efficacy and safety of newer oral anticoagulants. A literature search was performed for oral anticoagulants in advanced stages of development using PubMed and abstracts from thrombosis meetings. Most clinical trial data have demonstrated equal or superior efficacy in venographic endpoints in comparison to low-molecular-weight heparins (LMWH). However, bleeding complications have been reported to occur with oral anticoagulants as frequently as or more frequently than with LMWH. Other potential complications reported include liver enzyme elevation and cardiac irregularities. It remains to be established whether newer oral anticoagulants will be better alternatives to the current standard-ofcare in real-life medical clinical practice.

Original languageEnglish (US)
Pages (from-to)45-57
Number of pages13
JournalThrombosis and Haemostasis
Volume106
Issue number1
DOIs
StatePublished - Jul 1 2011

Keywords

  • Oral anticoagulants
  • Prophylaxis
  • Safety
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?'. Together they form a unique fingerprint.

  • Cite this